In very rare cases, people who underwent brain surgery as children have developed cerebral amyloid angiopathy in middle age, hinting that those procedures had transmitted seeds of misfolded Aβ. Though ...

The Alzheimer’s genetic hit list just got a little longer. A cadre of scientists, led by Emil Uffelmann, Douglas Wightman, and Danielle Posthuma at VU Amsterdam in the Netherlands, and Ole Andreassen ...

Scientists have puzzled over the fact that people who get Alzheimer’s disease at a young age carry a higher burden of tau pathology than do those who get it when they are older. In the November 4 ...

Calling all lipid enthusiasts! Scientists have put together a three-dimensional map of where these molecules reside throughout the entire mouse brain. Using high-tech mass-spec imaging, researchers ...

To mark the 20th anniversary of Alzforum's launch in 1996, we have compiled a timeline reflecting the evolution of Alzheimer’s disease research, starting from Alois Alzheimer's public presentation of ...

The competition supports research projects that develop and implement Artificial Intelligence (AI) and technology approaches to improve the health and well-being of older adults, including people ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

These Gba1 knock-in (KI) mice carry a leucine to proline mutation (L444P) in exon 10 of the mouse Gba1 (glucosidase [GCase], beta, acid 1) gene, resulting in Gba deficiency (Ginns et al., 2014; The ...

Not so long ago, a blood test for Alzheimer’s disease seemed a pipe dream. Now, after years of study, the field is awash with sensitive assays that signal the proteopathic culprits Aβ and tau ...

A record 4,700 people from 70 countries attended the 18th International Conference on Alzheimer’s and Parkinson’s Diseases, held March 5 to 9 in Lisbon, Portugal. Those who attended this hybrid ...

In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...